Elotuzumab is an anti-signaling lymphocytic activation molecule F7 (SLAMF7) monoclonal antibody, which is used to treat relapsed/refractory multiple myeloma (MM) [1]. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.